Get the Stockscreener App
1.50
2.74%
0.04
Acurx Pharmaceuticals Inc stock is traded at $1.50, with a volume of 84,363.
It is up +2.74% in the last 24 hours and down -6.25% over the past month.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
See More
Previous Close:
$1.46
Open:
$1.47
24h Volume:
84,363
Relative Volume:
0.71
Market Cap:
$6.45M
Revenue:
-
Net Income/Loss:
$-7.50M
P/E Ratio:
-0.3406
EPS:
-4.4035
Net Cash Flow:
$-6.14M
1W Performance:
-6.25%
1M Performance:
-6.25%
6M Performance:
-48.81%
1Y Performance:
-84.97%
1-Day Range:
$1.44
$1.52
1-Week Range:
$1.34
$1.74
52-Week Range:
$1.3259
$10.10
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.50 | 6.45M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - ad-hoc-news.de
What date does Acurx Pharmaceuticals's (ACXP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Clostridium Difficile Infections Market Forecast Signals - openPR.com
Price to book forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ACXP) - TradingView
ACXP Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to sales forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to revenue forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Enterprise value to EBIT forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals StockLong-term strategy and pipeline in focus - AD HOC NEWS
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx presents research on ibezapolstat mechanism at Leiden conference - Investing.com UK
Inside Acurx’s 3.2Å look at a new antibiotic for drug‑resistant bacteria - Stock Titan
Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
ACXP Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesEarnings Forecast Report - newsline.com
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals (ACXP) Stock Slides Slightly as Price Tests SupportMcClellan Oscillator - newsline.com
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Trend Analysis - newsline.com
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Yahoo Finance
Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics - AD HOC NEWS
Acurx Pharmaceuticals (ACXP) Declines 6.74% as Stock Nears Key Support at $1.71Rip Sell Trade - newsline.com
Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq - AD HOC NEWS
ACXPAcurx Pharmaceuticals Inc Latest SEC Filings - Finviz
ACXP Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Progress ContinuesDividend Growth Analysis - The Legal Advocate
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (ACXP) Holds Near Key Support as Small Decline Signals ConsolidationEqual Weight ETF - newsline.com
Acurx Pharmaceuticals (ACXP) Nudges Higher as Stock Approaches ResistanceChandelier Stop - thelegaladvocate.com
Acurx Pharmaceuticals Reports First Quarter 2026 Results, Highlights Ibezapolstat Phase 3 Trial for CDI Treatment - geneonline.com
ACXP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ACXP Q1 2026 Earnings: Narrowed Loss Surprises as Acurx Advances Lead CandidateGuidance Upgrade Report - newsline.com
ACXP Stock Price, Quote & Chart | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - ACCESS Newswire
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):